Crossmark

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

Crossref DOI link: https://doi.org/10.1186/s12885-019-5709-y

Published Online: 2019-05-23

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Werutsky, Gustavo

Maluf, Fernando Cotait

Cronemberger, Eduardo Henrique

Carrera Souza, Vinicius

dos Santos Martins, Suelen Patricia

Peixoto, Fábio

Smaletz, Oren

Schutz, Fábio

Herchenhorn, Daniel

Santos, Telma

Mavignier Carcano, Flavio

Queiroz Muniz, David

Nunes Filho, Paulo R. S.

Zaffaroni, Facundo

Barrios, Carlos

Fay, André
Funding

Funding for this research was provided by:

Janssen-Cilag Farmacêutica Ltda
License Information

Text and Data Mining valid from 2019-05-23

Version of Record valid from 2019-05-23
More Information

Article History

Received: 5 May 2018

Accepted: 14 May 2019

First Online: 23 May 2019

Ethics approval and consent to participate

: This study is currently on-going in 11 sites in Brazil, all of which had study documents (final protocol, any amendments, the informed consent form, applicable recruiting materials, and subject compensation programs) approved by Institutional Ethics Committee. All study participants provided written informed consent before any study procedure.

: Not applicable.

: This study has received funding from a commercial organization. Otherwise, the authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below